Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis
NCT06324812Phase 2Completed
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- Jul 2024
- Primary completion
- May 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SSGJ-611 in atopic dermatitis (AD), sponsored by 3S Guojian Pharmaceutical. Started Jul 2024; status: completed.
02
Drugs
SSGJ-611
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06324812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06324812.